Events
Reframing RAS in NSCLC: Biological Heterogeneity, Diagnostic Implications, and Novel Targeted Strategies
Room 202, ASEM Ballroom, 2F
Presented by Revolution Medicines, Inc.
Unlocking Antibody Innovation: Emerging Bispecifics and ADCs in Advanced NSCLC
Room 103, Grand Ballroom, 1F
Presented by Pfizer.
Management of Heavily Pretreated ES-SCLC: Current Evidence and Future Directions
Room 202, ASEM Ballroom, 2F
Presented by MSD.
The Next Generation of ADC-Driven Lung Cancer Care
Room 202, ASEM Ballroom, 2F
Presented by AbbVie.
The CROWN Trial at 7 Years: The Potential for Transforming Treatment of 1L ALK+ mNSCLC Toward a Chronic Care Model
Room 103, Grand Ballroom, 1F
Presented by Pfizer.
Optimizing Immunotherapy Strategies Across the NSCLC Treatment Continuum
Room 103, Grand Ballroom, 1F
Presented by BeOne Medicines.
From Evidence to Early Adoption: A Comprehensive Approach to the Management of HER2-Mutant NSCLC
Room 103, Grand Ballroom, 1F
Presented by Bayer.
Enhancing Outcomes in Early-Stage Lung Cancer Through MDT Collaboration: Integrating Immunotherapy and Local Treatments
Auditorium, 3F
Presented by AstraZeneca.
Breaking the Blood-Brain Barrier: The Emerging Role of ADCs in Lung Cancer Brain Metastases
Room E5, Conference Room E, 3F
Presented by Daiichi Sankyo, Inc.
The First Move Matters: Personalising First-Line EGFR+ NSCLC Treatment for Optimal Survival Outcomes
Room 202, ASEM Ballroom, 2F
Presented by Johnson & Johnson.
From Plasma to Practice: Clinical Interpretation of Methylation Signals in Advanced NSCLC
Room 103, Grand Ballroom, 1F
Presented by Guardant Health.
EGFR and HER2: Navigating Shifting Paradigms with Targeted Therapies in mNSCLC Clinical Practice
Auditorium, 3F
Presented by AstraZeneca.
Changing the Trajectory of NSCLC Survival
Room 202, ASEM Ballroom, 2F
Presented by MSD.



